Alerje has raised $410K in total across 1 funding round.
Alerje's investors include Blue Victor Capital, Collaborative Seed & Growth Partners, LongJump VC, Pario Ventures, Joshua Webster, Ozzy Akay.
Alerje is a Detroit-based digital health company founded in 2016 that develops AI-powered platforms and hardware for managing food allergies, primarily through its FAIT (Food Allergy Immunotherapy Tracking) platform and the Omniject smartphone-attached epinephrine auto-injector[1][3][5]. It serves families, allergists, clinics, insurers, and pharma companies affected by food allergies—impacting 32 million Americans, with rapid growth among Black and Brown children—by solving challenges in oral immunotherapy (OIT) adherence, emergency response, and data-driven decision-making[2][5]. The platform collects, analyzes, and shares clinical data via mobile apps for dose tracking, progress visualization, clinic messaging, and proactive alerts, while Omniject enhances EpiPen storage, convenience, and safety with automated notifications[1][3][5]. Alerje has raised $3.26M, including a $1M NSF Phase II SBIR grant in 2023, holds 5 patents (focused on allergology and food allergies), and shows growth via partnerships (e.g., Mitsubishi, Monsha'at) and a 2024 acquisition of its autoinjector platform by Sempresto[1][4].
Alerje was founded in 2016 by Javier Evelyn, a Detroit entrepreneur and app developer who personally suffers from severe food allergies, motivating him to address the inconveniences of EpiPens—expensive, bulky, easy to forget, and hard to manage during emergencies[1][3]. After leading sales at an independent insurance agency, Evelyn left his career to build a food allergy management platform, starting with support from Michigan Economic Development Corporation (MEDC), Invest Detroit for financial modeling and investor intros, and early angel funding[3]. Key pivots included NSF-validated OIT software (Phase I grant in 2021, Phase II $1M in 2023), the 2021 patent for Omniject, and joining StartUp Health in 2020 as one of the first in their health equity cohort[2][3][4]. Early traction came from pilots, comic series for kids, and CES showcases, humanizing the mission around improving quality of life for underserved demographics[2][3][4].
Alerje rides the digital health and OIT wave, where childhood food allergies have risen 50% since 2007 amid growing early intervention methods, yet clinics/families lack scalable monitoring tools—FAIT fills this with AI for proactive care in a market projected at $11.3B by 2030[5]. Timing aligns with post-pandemic health tech demand, health equity pushes (e.g., StartUp Health cohort), and regulatory tailwinds like NSF grants/SBIR funding[2][4]. Market forces favoring it include rising prevalence, insurer/pharma need for data, and hardware-software convergence (e.g., smartphone integration over clunky EpiPens)[1][3]. It influences the ecosystem by pioneering AI-OIT adherence, enabling pharma trials, and inspiring global partnerships (Saudi Vision 2030, Mitsubishi), while its 2024 autoinjector sale signals maturing digital allergy management[4].
Alerje's FAIT platform launches in 2026, poised to commercialize fully post-pilots with recent strategic funding and partnerships driving dense rollout[2][4][5]. Trends like AI health equity, OIT mainstreaming, and integrated wearables will shape it, potentially expanding to predictive reaction analytics or global scaling via alliances. Post-acquisition, expect Omniject evolution under Sempresto, amplifying Alerje's software focus and influence in transforming food allergies from fear to "food freedom"—building on Evelyn's personal drive to redefine allergy care for millions[3][5].
Alerje has raised $410K across 1 funding round. Most recently, it raised $410K Seed in August 2017.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2017 | $410K Seed | Blue Victor Capital, Collaborative Seed & Growth Partners, LongJump VC, Pario Ventures, Joshua Webster, Ozzy Akay |
